1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Immuno-Oncology Outlook: Getting To The Root Of Head And Neck Cancer

 
• By Emily Hayes

As PD-1 inhibitors march toward earlier-stage head and neck cancers, researchers consider ways to improve the precision of immunotherapy through better patient selection and combinations for this accessible tumor type.

Mouth Anatomy

With Phase III trials ongoing of leading PD-1/L1 inhibitors in first-line treatment of recurrent or metastatic cancers of the head and neck, new research already is moving the future target to the neoadjuvant setting, prior to surgery and chemoradiation, with curative intent.

Squamous cell carcinomas of the head and neck (SCCHN or HNSCC) include tumors that start in the mouth, nose and throat and salivary glands

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

More from Anticancer